Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
With a mission to support novel approaches to managing and preventing heart failure, the Ted Rogers Centre for Heart Research uses its Innovation Fund to propel emerging research with great potential. In our 2024-25 Innovation Seed Grant competition, the Centre funded...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
3D models of heart failure… stiffened hearts in diabetes…. saving infant lives
After a heart attack, this peptide protects the heart from further injury
Featured Event
Heart Failure Symposium 2025
Virtual Library
Visit our YouTube channel filled with world-class heart failure educational sessions on diverse topics
Almost 20 years ago, a hallway conversation kickstarted Dr. Mansoor Husain’s journey in helping create and test a new diabetes drug that reduces the risk of heart disease.
In 2019, the Ted Rogers Centre for Heart Research executive director published the findings of a landmark trial proving the drug’s safety and reduction in cardiovascular-related mortality, bringing a new therapy into the fold for patients with diabetes – who are two to four times more likely to die from cardiovascular problems than those without it.
In this podcast, produced by University Health Network, explore the fascinating intersection of type 2 diabetes and heart failure, and the recent journey to discover that treatments for the former can be effective for the latter.